CVS Health data puts a price on GLP-1 break-even: $350 a month

Real-world Aetna claims data finds clinical benefits are real, but costs still outpace medical savings at today’s prices
CVS Health data puts a price on GLP-1 break-even: $350 a month
GROUP BENEFITS
By Mark Rosanes
Nov 16, 2026

Glucagon-like peptide-1 (GLP-1) drugs reduce hospitalizations, lower the odds of heart attack, and cut emergency department visits. At current prices, they still cost more than they save. That is the core finding of a new whitepaper from CVS Health, and it carries direct implications for employers and advisors making a coverage decision heading into 2027 plan design.

The study, GLP-1s: Good Drugs, High Prices, used anonymized Aetna claims data from commercially fully insured members, with index years 2023 to 2025 and up to three years of follow-up. Researchers matched GLP-1 users with similar non-users based on age, existing health conditions, prior healthcare utilization, and medical and pharmacy spending.

The clinical findings were consistent with trial data. GLP-1 initiators had hospitalization rates 34% to 42% lower than matched non-users across the three-year follow-up period, emergency department visit rates 10% to 12% lower in years one and two, and 14% lower odds of major adverse cardiovascular events in earlier analyses. Patients who stayed on therapy for at least 80% of days saw even sharper reductions. Hospitalization rates were 53% to 66% lower, and ED visit rates were 27% to 33% lower.

Where the economics break down

The clinical benefit did not translate into net savings. In the year-three analysis, medical spending was $9,400 lower per member among all initiators, but net pharmacy spending was $13,300 higher, producing a net cost increase of approximately $3,900 per member. Among adherent members, medical savings were larger at $13,000, but so was the net cost gap. Pharmacy spending rose $20,300, leaving a $7,300 net increase. CVS Health noted that the year-three cohort was smaller than earlier analyses, making some differences harder to distinguish from chance.

CVS Health’s internal modeling suggests a net price of approximately $350 per month over three years would bring pharmacy spending and observed medical savings into balance for the overall study population. That figure varies by patient risk profile, adherence, and indication. A high-risk patient with type 2 diabetes, for example, generates faster near-term medical savings than a younger patient whose primary indication is obesity.

The $350 estimate lands at a moment when cash-pay pricing is already reshaping the market. Novo Nordisk and Eli Lilly have partnered with the federal TrumpRx platform to offer GLP-1 therapies directly to consumers at prices below standard list. Eli Lilly’s direct employer program, Employer Connect, launched in March 2026 offering the Zepbound KwikPen, a multi-dose device format, at a flat net price of $449 per month. Cash-pay access is widening, but as CVS Health notes, lower cash prices alone do not solve the coverage equation for insured populations.

The adherence paradox

One finding benefits advisors should work through carefully with clients is the adherence data. Patients who stayed on GLP-1 therapy consistently delivered better clinical outcomes, but their total cost of care was higher than less-adherent initiators, because they used more of the drug. That means supporting adherence through lifestyle coaching, clinical follow-up, and side-effect management is only sustainable if it goes hand in hand with pricing that makes long-term use affordable. Without that, adherence programs improve outcomes while widening the cost gap.

Jennifer Collier, president of health and risk solutions at Sun Life US in Wellesley Hills, Massachusetts, made a similar point when examining what drives patients off GLP-1 therapy. “Most Americans don’t have $800, $1,000 in disposable cash,” she said. “They want to have the benefits. It’s not for lack of want, but then you get into a decision between my finances and my health choices.”

This is not a new tension for plan sponsors. Employers have been pulling back on GLP-1 coverage for weight loss throughout 2026 as pharmacy costs have risen. The Kaiser Family Foundation’s 2026 Employer Health Benefits Survey found average annual family premiums reached $28,303 this year, up 5% from 2025. With GLP-1s now accounting for a growing share of that spend, the question of who gets coverage and under what clinical criteria is one of the most consequential plan design decisions employers face.

The CVS Health report frames the coverage decision around three conditions: treating patients most likely to benefit based on clinical evidence, supporting adherence while those patients are on therapy, and negotiating prices that make broader access economically viable. The report argues against using financial break-even as the sole test of coverage, while also being clear that price is the lever most likely to close the gap between what GLP-1s deliver clinically and what they cost in practice.

Amy Compton-Phillips, MD, a co-author of the report and executive vice president and chief medical officer at CVS Health, said at the HLTH conference in Las Vegas on November 15, that GLP-1s are effective medicines with real health benefits, and that the challenge is making those benefits affordable at scale.

Related Stories
Free newsletter

We'll keep you up-to-date with the latest breaking news, cutting edge opinion, and expert analysis affecting both your business and the industry as whole.

Free newsletter

Our daily newsletter is FREE and keeps you up - to - date with the world of Insurance. Please complete the form below and click on subscribe for daily newsletters from IB US.